Long-term efficacy and safety of PRO 160/120 (a combination of Sabal and Urtica extract) in patients with lower urinary tract symptoms (LUTS)

Phytomedicine

Volumn 10, Issue SUPPL. 4, 2003, Pages 53-55

  Bondarenko, Boris ^a,c   Walther, Carola ^b   Funk, Petra ^b   Schläfke, Sandra ^b   Engelmann, Udo ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; PRO 160 120; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; UNCLASSIFIED DRUG; URTICA EXTRACT; WS 1031; WS 1473;

ARTICLE; CAPSULE FILLING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; LOWER URINARY TRACT SYMPTOM; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SABAL; TREATMENT OUTCOME; URETHRA DISEASE; URINE FLOW RATE; URTICA DIOICA;

SABAL; URTICA; URTICA DIOICA;

EID: 0038249060     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1078/1433-187X-00352     Document Type: Article

References (18)

1. Alken CE (1973) Leitfaden der Urologie. Thieme, Stuttgart: 180-182
2. Berges RR, Pientka L, Höfner K, Senge T, Jonas U (2001) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 39: 682-687
3. Bondarenko B, Walther C, Schläfke S, Engelmann U (2002) Langzeittherapiestudie zur Wirksamkeit und Verträglichkeit von PRO 160/120 (Kombination aus Sabal- und Urtica-Extrakt) und Tamsulosin bei Patienten mit LUTS. Available at: http://193.97.204.182/dgu2002/abs/sheets/ABS00489.HTM. Accessed March 13, 2003
4. Buck AC (1996) Phytotherapy for the prostate. Br J Urol 78: 325-336
5. Düker E-M, Kopanski L, Schweikert HU (1989) Inhibition of 5α-reductase activity by extracts from Sabal serrulata. Planta Med 55: 587
6. Goepel M, Hecker U, Krege S, Rübben H, Michel MC (1999) Saw palmetto extracts potently and noncompetitively inhibit human α1-adrenoceptors in vitro. Prostate 38: 208-215
7. +ATPase of the benign prostatic hyperplasia. Planta Med 60: 30-33
8. Koch E (2001) Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med 67: 489-500
9. Koch E, Biber A (1994) Pharmakologische Wirkungen von Sabal- und Urtikaextrakten als Grundlage für eine rationale medikamentöse Therapie der benignen Prostatahyperplasie. Urologe B 34: 95-100
10. Lichius JJ, Lenz C, Lindemann P, Müller H-H, Aumüller G, Konrad L (1999) Antiproliferative effect of a polysaccharide fraction of a 20% methanolic extract of stinging nettle roots upon epithelial cells of the human prostate (LNCaP). Pharmazie 54: 768-771
11. Metzker H, Kieser M, Hölscher U (1996) Wirksamkeit eines Sabal-Urtica-Kombinationspräparats bei der Behandlung der benignen Prostatahyperplasie (BPH). Urologe B 36: 292-300
12. Roehrborn CG, Abbou CC, Akaza H et al. (2001) Clinical research criteria for studies of: lower urinary tract symptoms (LUTS), enlarged prostate gland (EPG) bladder outlet obstruction (BOO) and benign prostatic hyperplasia (BPH). In: Benign Prostatic Hyperplasia. 5th International Consultation on Benign Prostatic Hyperplasia (BPH) - June 25-28, 2000, Paris (eds Chatelain C et al.): 317-395. Health Publication Ltd, Plymouth PL6 7PY, United Kingdom
13. Roehrborn CG, Abbou CC, Allona-Almagro A et al. (1998) BPH: Clinical Research Criteria. In: 4th International Consultation on BPH. Paris, July 2-5, 1997. Proceedings (eds Denis L et al.): 439-491. Scientific Communication International, Jersey JE4 8WZ, Channel Islands
14. Schneider B, Sökeland J (1997) Phytotherapie bei benigner Prostatahyperplasie (BPH) - Ergebnisse einer Umfrage. Urologe B 37: 113-115
15. Sivkov A, Köhler S, Engelmann U, Medvedev A, Lopatkin N (2001) Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS - a placebo-controlled, double-blind, multicenter trial. Urologe A 40 (Suppl 1): S19
16. Sökeland J (2000) Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. Br J Urol 86: 439-442
17. Sökeland J, Albrecht J (1997) Kombination aus Sabal- und Urticaextrakt vs. Finasterid bei BPH (Stad. I bis II nach Alken). Vergleich der therapeutischen Wirksamkeit in einer einjährigen Doppelblindstudie. Urologe A 36: 327-333
18. Treagust J, Morkane T, Speakman M (2001) Estimating a population's needs for the treatment of lower urinary tract symptoms in men: what is the extent of unmet need? J Public Health Med 23:141-147